Campbell Lab

Research focus

NIH R01 · 2025

Plasminogen in glomerular disease progression

Project Summary Despite significant evidence identifying the podocyte as the key glomerular cell target for injury, validated therapeutic targets are scarce and commercially available cell-specific therapy is lacking. Additionally, given the heterogeneous nature of proteinuric kidney disease, biomarkers to identify patients at high versus low risk for progression to end-stage kidney disease (ESKD) are needed. Our long-term goal is to identify key regulatory pathways and therapeutic targets in the treatment of proteinuric kidney disease. We previously identified the serine protease plasminogen as a mediator of direct podocyte injury and a potential targetable urinary biomarker that…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.